Ancora Advisors’s Haemonetics HAE Stock Holding History

Ancora Advisors’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-25	Closed	-$2.13K	–	1798
2023 Q2	$2.13K	Hold	25	–	–	﹤0.01%	1476
2023 Q1	$2.07K	Hold	25	–	–	﹤0.01%	1518
2022 Q4	$2K	Hold	25	–	–	﹤0.01%	1588
2022 Q3	$2K	Hold	25	–	–	﹤0.01%	1789
2022 Q2	$2K	Hold	25	–	–	﹤0.01%	1942
2022 Q1	$2K	Hold	25	–	–	﹤0.01%	2135
2021 Q4	$1K	Hold	25	–	–	﹤0.01%	2280
2021 Q3	$2K	Hold	25	–	–	﹤0.01%	2038
2021 Q2	$2K	Hold	25	–	–	﹤0.01%	1823
2021 Q1	$3K	Hold	25	–	–	﹤0.01%	1601
2020 Q4	$3K	Hold	25	–	–	﹤0.01%	1340
2020 Q3	$2K	Hold	25	–	–	﹤0.01%	1315
2020 Q2	$2K	Hold	25	–	–	﹤0.01%	1275
2020 Q1	$2K	Buy	+25	New	+$2.71K	﹤0.01%	1357

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Ancora Advisors's HAE Position: Q3 2023 in Review

Ancora Advisors sold out of Haemonetics (HAE) in Q3 2023, closing a stake of 25 shares — an estimated $2.13K sold.

Ancora Advisors first reported a position in HAE in Q1 2020 and held it in 14 quarters. The position peaked at $3K in Q1 2021. 296 funds tracked by Wall St. Rank hold HAE as of Q3 2023.

Ancora Advisors reported no remaining Haemonetics position as of Q3 2023 after selling out during the quarter.
Ancora Advisors sold 25 Haemonetics shares in Q3 2023, an estimated $2.13K.
Ancora Advisors first reported a position in Haemonetics in Q1 2020 and held it in 14 quarters.
Ancora Advisors's Haemonetics position peaked at $3K in Q1 2021.
296 funds tracked by Wall St. Rank held Haemonetics as of Q3 2023.

Based on Ancora Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.